Vaughn Victor 4
4 · SUPERNUS PHARMACEUTICALS INC · Filed Apr 20, 2018
Insider Transaction Report
Form 4
Vaughn Victor
Senior Vice President of Sales
Transactions
- Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-04-19−7,850→ 38,400 totalExercise: $25.30Exp: 2027-02-24→ Common Stock (7,850 underlying) - Exercise/Conversion
Common Stock
2018-04-19$25.30/sh+7,850$198,605→ 17,194 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-04-18−3,750→ 46,250 totalExercise: $25.30Exp: 2027-02-24→ Common Stock (3,750 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-04-18−6,250→ 25,000 totalExercise: $12.98Exp: 2026-03-01→ Common Stock (6,250 underlying) - Exercise/Conversion
Common Stock
2018-04-18$12.98/sh+6,250$81,125→ 15,594 total - Sale
Common Stock
2018-04-18$47.06/sh−10,000$470,617→ 9,344 total - Sale
Common Stock
2018-04-19$49.03/sh−7,850$384,855→ 9,344 total - Exercise/Conversion
Common Stock
2018-04-18$25.30/sh+3,750$94,875→ 19,344 total
Footnotes (5)
- [F1]Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.25, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.15, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- [F4]The option became exercisable in four equal installments beginning on March 1, 2017, which was the first anniversary of the date on which the option was granted.
- [F5]The option became exercisable in four equal installments beginning on February 24, 2018, which was the first anniversary of the date on which the option was granted.